Key result
Coronary microvascular dysfunction linked to HFpEF development, driven by cardiometabolic risk factors and a pro-inflammatory state.
Why the study?
Coronary microvascular dysfunction has been associated with HFpEF development, but clinical evidence remains limited, prompting a review of the data linking CMD to HFpEF and potential management targets.
Design
Literature review
Authors
Loading...
Coronary microvascular dysfunction, driven by cardiometabolic risk factors and systemic inflammation, is increasingly recognized as a key pathophysiological mechanism in the development of HFpEF, highlighting the need for targeted diagnostic and therapeutic strategies.
Coronary microvascular dysfunction, driven by cardiometabolic risk factors and systemic inflammation, is increasingly recognized as a key pathophysiological mechanism in the development of HFpEF, highlighting the need for targeted diagnostic and therapeutic strategies.
Bond et al. (2025) conducted a review in Heart failure with preserved ejection fraction (HFpEF) and Coronary microvascular dysfunction (CMD). Coronary microvascular dysfunction, driven by cardiometabolic risk factors and a pro-inflammatory state, may play a significant role in the development of heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: